atenolol has been researched along with Cardiovascular Diseases in 131 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 9.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "The aim of this study was to analyze the cost-effectiveness of losartan compared with atenolol in the treatment of stroke from the Dutch health care perspective." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 9.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 9.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 9.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "A total of 4327 men and women, aged > or = 60 years, with isolated systolic hypertension, randomized to placebo or chlorthalidone, with the addition of atenolol or reserpine if needed, were observed for 5 years." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 9.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 9.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 6.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials." | 5.22 | Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. ( Esler, M; Grassi, G; Kjeldsen, SE; Kreutz, R; Mancia, G; Pathak, A, 2022) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| "We examined the effect of chlorthalidone-based stepped care on the competing risks of cardiovascular (CV) versus non-CV death in the Systolic Hypertension in the Elderly Program (SHEP)." | 5.19 | Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Kostis, WJ; Messerli, FH; Sedjro, JE; Swerdel, JN, 2014) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "ECG strain was evaluated at baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hypertension) treated in a blinded manner with atenolol- or losartan-based regimens." | 5.14 | Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2009) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.12 | The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. ( Brady, WE; Dahlöf, B; Devereux, RB; Fossum, E; Gleim, GW; Hille, DA; Julius, S; Kizer, JR; Kjeldsen, SE; Lyle, PA, 2007) |
| "The aim of this study was to analyze the cost-effectiveness of losartan compared with atenolol in the treatment of stroke from the Dutch health care perspective." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001." | 5.11 | Prognostic significance of left ventricular mass change during treatment of hypertension. ( Aurup, P; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Harris, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Wachtell, K, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study." | 5.11 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. ( Aurup, P; Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Snapinn, S; Wedel, H, 2004) |
| " The aim of the LIFE-study was to establish whether treatment with the angiotensin-II AT 1-receptor antagonist, losartan, reduced cardiovascular events more effectively than treatment with the betablocker atenolol in patients with hypertension and left ventricular hypertrophy." | 5.10 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Pedersen, OL, 2003) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study." | 5.10 | Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Helle Berg, S; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2003) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was conducted between 1995 and 2001 to compare the incidence of cardiovascular morbidity and mortality with losartan- or atenolol-based treatment in 9193 patients aged 55 to 80 years with hypertension and left ventricular hypertrophy." | 5.10 | An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Devereux, RB; Fyhrquist, F; Kjeldsen, SE; Kristianson, K; Lindholm, LH; Lyle, PA; Nieminen, MS; Snapinn, SM, 2003) |
| "These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment." | 5.10 | Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristiansson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "A total of 4327 men and women, aged > or = 60 years, with isolated systolic hypertension, randomized to placebo or chlorthalidone, with the addition of atenolol or reserpine if needed, were observed for 5 years." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 5.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) is a prospective, randomized, double-blind, multinational trial comparing effects of 4-year treatment based on the long-acting, highly lipophilic calcium antagonist lacidipine with those of treatment based on the beta-blocker atenolol on the development of carotid artery wall alterations in patients (aged 45-75 years) with mild-to-moderate hypertension (systolic blood pressure 150-210 mmHg and diastolic blood pressure 95-115 mmHg)." | 5.08 | Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Ravinetto, R; Reid, J; Rodicio, J; Safar, M; Zanchetti, A, 1998) |
| "To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke." | 4.88 | A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. ( Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO, 2012) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| "Although most guidelines committees historically recommended initial diuretics and/or β blockers for uncomplicated hypertension, clinical trial outcomes analyzed in the last 5 to 7 years have been suboptimal with atenolol, the world's most popular β blocker." | 3.77 | Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? ( Childers, WK; Elliott, WJ, 2011) |
| "We evaluated the effects of nebivolol, a third-generation highly selective [beta]-blocker with additional vasodilating activity, versus the traditional [beta]-blocker atenolol in controlling functional and morphological cardiovascular damage in a rat model of metabolic syndrome." | 3.76 | Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, F; Giani, J; Munoz, M; Rivas, C; Toblli, J, 2010) |
| "To assess the cost effectiveness of four alternative treatment strategies in patients with hypertension and three or more cardiovascular risk factors in the UK (from the UK NHS perspective) or Sweden (from the societal perspective): amlodipine-based plus atorvastatin, atenolol-based plus atorvastatin, amlodipine-based alone and atenolol-based alone." | 3.75 | The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "The low event rates for all cohorts suggest that atenolol has not been associated with a significant burden of cardiovascular morbidity or mortality in its traditional role for uncomplicated hypertension." | 3.74 | Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. ( Blackburn, DF; Blackburn, JL; Dobson, RT; Eurich, DT; Johnson, JA; Lamb, DA; Wilson, TW, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "This study compares the antihypertensive and lipid modifying effects of treatment of mild to moderate hypertension with celiprolol or atenolol." | 3.69 | A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. ( Jackson, RT; Milne, RJ; Vander Hoorn, S, 1997) |
| "Dietary sodium, the main determinant of the pharmacodynamic response to renin-angiotensin system blockade, influences the pharmacokinetics of various cardiovascular drugs." | 2.78 | Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. ( Azizi, M; Blanchard, A; Charbit, B; Ezan, E; Funck-Brentano, C; Ménard, J; Peyrard, S; Wuerzner, G, 2013) |
| "The bioavailability of the ingredients of the Polycap (T; test) when formulated as a single capsule was compared with that of identical capsules with each of its ingredients administered separately (R; reference) in a five-arm, randomized, single-dose, two-period, two-treatment, two-sequence, crossover trial with at least a 2-week washout period in a total of 195 healthy volunteers." | 2.75 | Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. ( Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T, 2010) |
| "Amlodipine-based treatment was associated with a smaller arteriolar length:diameter ratio than atenolol-based treatment (13." | 2.74 | Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. ( Allemann, S; Chaturvedi, N; Hughes, A; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Stanton, A; Stettler, C; Tapp, R; Thom, S; Witt, N, 2009) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class." | 2.42 | Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Devereux, RB; Lyle, PA, 2004) |
| "Such combination is very useful for treating various cardiovascular diseases (CVD) including high blood pressure, hypercholesterolemia in addition to its antiplatelet aggregating activity." | 1.56 | Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools. ( Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A, 2020) |
| "Metoprolol treatment produced a slight but significant reduction in serum glucose levels with elevation in serum insulin levels, while atenolol produced a slight increase in glucose levels but no effect on insulin levels." | 1.34 | Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. ( Bhadada, SV; Goyal, RK, 2007) |
| " These differences account for many of the observed variations in drug action and dosage scheduling as well as for some of the side effects." | 1.27 | Beta-adrenergic blockers. Choosing among them. ( McGoon, MD; Vlietstra, RE, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.76) | 18.7374 |
| 1990's | 14 (10.69) | 18.2507 |
| 2000's | 70 (53.44) | 29.6817 |
| 2010's | 41 (31.30) | 24.3611 |
| 2020's | 5 (3.82) | 2.80 |
| Authors | Studies |
|---|---|
| Esler, M | 1 |
| Kjeldsen, SE | 27 |
| Pathak, A | 1 |
| Grassi, G | 1 |
| Kreutz, R | 1 |
| Mancia, G | 4 |
| Wata, D | 1 |
| Ogwu, J | 1 |
| Dunford, L | 1 |
| Lawson, G | 1 |
| Tanna, S | 1 |
| Elsonbaty, A | 1 |
| Serag, A | 1 |
| Abdulwahab, S | 1 |
| Hassan, WS | 1 |
| Eissa, MS | 1 |
| Yusuf, S | 5 |
| Joseph, P | 2 |
| Dans, A | 1 |
| Gao, P | 3 |
| Teo, K | 3 |
| Xavier, D | 5 |
| López-Jaramillo, P | 2 |
| Yusoff, K | 2 |
| Santoso, A | 2 |
| Gamra, H | 2 |
| Talukder, S | 2 |
| Christou, C | 1 |
| Girish, P | 1 |
| Yeates, K | 2 |
| Xavier, F | 1 |
| Dagenais, G | 1 |
| Rocha, C | 1 |
| McCready, T | 1 |
| Tyrwhitt, J | 2 |
| Bosch, J | 2 |
| Pais, P | 5 |
| Huang, KY | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Su, KP | 1 |
| Matsuoka, YJ | 1 |
| Hsu, CW | 1 |
| Lin, CH | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| Lafeber, M | 1 |
| Spiering, W | 1 |
| Visseren, FL | 1 |
| Grobbee, DE | 2 |
| Bots, ML | 2 |
| Stanton, A | 4 |
| Patel, A | 4 |
| Prabhakaran, D | 2 |
| Webster, R | 2 |
| Thom, S | 3 |
| Rodgers, A | 5 |
| Duprez, DA | 1 |
| Florea, N | 1 |
| Duval, S | 1 |
| Koukol, C | 1 |
| Cohn, JN | 1 |
| Okada, M | 1 |
| Falcão, LFR | 1 |
| Ferez, D | 1 |
| Martins, JL | 1 |
| Errante, PR | 1 |
| Rodrigues, FSM | 1 |
| Caricati-Neto, A | 1 |
| Marinho, M | 1 |
| Fenelon, G | 1 |
| Oliveira-Júnior, IS | 1 |
| Gupta, A | 1 |
| Mackay, J | 1 |
| Whitehouse, A | 1 |
| Godec, T | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Poulter, N | 3 |
| Sever, P | 2 |
| Dans, AL | 1 |
| Lopez, PC | 1 |
| Gaziano, TA | 1 |
| Pandya, A | 1 |
| Sy, S | 1 |
| Jardim, TV | 1 |
| Ogden, JM | 1 |
| Weinstein, MC | 1 |
| Azizi, M | 1 |
| Blanchard, A | 1 |
| Charbit, B | 1 |
| Wuerzner, G | 1 |
| Peyrard, S | 1 |
| Ezan, E | 1 |
| Funck-Brentano, C | 1 |
| Ménard, J | 1 |
| Field, J | 1 |
| Reddy, KS | 1 |
| Cidambi, R | 1 |
| Bompoint, S | 2 |
| Billot, L | 2 |
| Patel, BM | 1 |
| Bhadada, SV | 2 |
| Khor, KH | 1 |
| Shiels, IA | 1 |
| Campbell, FE | 1 |
| Greer, RM | 1 |
| Rose, A | 1 |
| Mills, PC | 1 |
| Kostis, JB | 3 |
| Sedjro, JE | 2 |
| Cabrera, J | 2 |
| Cosgrove, NM | 2 |
| Pantazopoulos, JS | 1 |
| Kostis, WJ | 2 |
| Pressel, SL | 2 |
| Davis, BR | 4 |
| Messerli, FH | 3 |
| Cheng, JQ | 1 |
| Swerdel, JN | 1 |
| Deng, Y | 1 |
| Cass, A | 1 |
| Peiris, D | 1 |
| Usherwood, T | 1 |
| Brown, A | 1 |
| Jan, S | 1 |
| Neal, B | 1 |
| Hillis, GS | 1 |
| Rafter, N | 2 |
| Tonkin, A | 1 |
| Burch, C | 1 |
| Burke, H | 1 |
| Hayman, N | 1 |
| Molanus, B | 1 |
| Reid, CM | 1 |
| Shiel, L | 1 |
| Togni, S | 1 |
| Wang, JG | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Selak, V | 1 |
| Elley, CR | 1 |
| Bullen, C | 1 |
| Crengle, S | 1 |
| Wadham, A | 1 |
| Parag, V | 1 |
| Harwood, M | 1 |
| Doughty, RN | 1 |
| Arroll, B | 1 |
| Milne, RJ | 2 |
| Bramley, D | 1 |
| Bryant, L | 1 |
| Jackson, R | 1 |
| Wong, MC | 1 |
| Tam, WW | 1 |
| Lao, XQ | 1 |
| Wang, HH | 1 |
| Kwan, MW | 1 |
| Cheung, CS | 1 |
| Tong, EL | 1 |
| Cheung, NT | 1 |
| Yan, BP | 1 |
| Yu, CM | 1 |
| Griffiths, SM | 1 |
| Vishram, JK | 1 |
| Dahlöf, B | 34 |
| Devereux, RB | 32 |
| Ibsen, H | 19 |
| Lindholm, LH | 18 |
| Okin, PM | 7 |
| Rothwell, PM | 1 |
| Wachtell, K | 15 |
| Olsen, MH | 11 |
| Bang, CN | 1 |
| Roman, MJ | 1 |
| Palmieri, V | 4 |
| Boman, K | 5 |
| Gerdts, E | 7 |
| Nieminen, MS | 20 |
| Papademetriou, V | 3 |
| Hille, DA | 7 |
| Wu, S | 1 |
| Xu, W | 1 |
| Wang, FR | 1 |
| Yang, XW | 1 |
| Holzgreve, H | 1 |
| Calaghan, S | 1 |
| Kozera, L | 1 |
| White, E | 1 |
| Mehlsen, J | 2 |
| Cazzola, M | 1 |
| Matera, MG | 1 |
| Ostergren, J | 1 |
| Poulter, NR | 2 |
| Sever, PS | 2 |
| Wedel, H | 10 |
| Beevers, G | 8 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kristinsson, A | 1 |
| McInnes, GT | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 2 |
| Sigamani, A | 3 |
| Pogue, J | 1 |
| Afzal, R | 3 |
| Escobar, C | 1 |
| Barrios, V | 1 |
| Oikarinen, L | 3 |
| Viitasalo, M | 2 |
| Toivonen, L | 2 |
| Edelman, JM | 5 |
| Eikelboom, J | 1 |
| Mohan, V | 1 |
| Gupta, R | 2 |
| Thomas, N | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Jönsson, B | 1 |
| Cockcroft, JR | 3 |
| Stettler, C | 1 |
| Witt, N | 1 |
| Tapp, R | 1 |
| Chaturvedi, N | 1 |
| Allemann, S | 1 |
| Mayet, J | 1 |
| Hughes, A | 1 |
| Warmack, TS | 1 |
| Estes, MA | 1 |
| Heldenbrand, S | 1 |
| Franks, AM | 1 |
| Beitelshees, AL | 1 |
| Navare, H | 1 |
| Wang, D | 2 |
| Gong, Y | 2 |
| Wessel, J | 1 |
| Moss, JI | 1 |
| Langaee, TY | 1 |
| Cooper-DeHoff, RM | 1 |
| Sadee, W | 2 |
| Pepine, CJ | 3 |
| Schork, NJ | 1 |
| Johnson, JA | 3 |
| Cartoafa, M | 1 |
| Agustí, MA | 1 |
| Shah, T | 1 |
| Shah, G | 1 |
| Jha, V | 1 |
| Ghosh, C | 1 |
| Desai, J | 1 |
| Khamar, B | 1 |
| Chakraborty, BS | 1 |
| Toblli, J | 1 |
| Cao, G | 1 |
| Rivas, C | 1 |
| Munoz, M | 1 |
| Giani, J | 1 |
| Dominici, F | 1 |
| Angerosa, M | 1 |
| Aurigemma, GP | 1 |
| Rokkedal, JE | 1 |
| van Mourik, MS | 1 |
| Cameron, A | 1 |
| Ewen, M | 1 |
| Laing, RO | 1 |
| Julius, S | 14 |
| Del Giaccio, A | 1 |
| Eblen-Zajjur, A | 1 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 1 |
| Kirby, S | 1 |
| Lawler, F | 1 |
| Welborn, TL | 1 |
| Fyhrquist, F | 12 |
| Silventoinen, K | 1 |
| Saijonmaa, O | 1 |
| Kontula, K | 1 |
| de Faire, U | 10 |
| Os, I | 2 |
| Lønnebakken, MT | 1 |
| Elliott, WJ | 2 |
| Childers, WK | 1 |
| Papp, AC | 1 |
| Pinsonneault, JK | 1 |
| Newman, LC | 1 |
| Kumari, M | 1 |
| Hingorani, AD | 1 |
| Talmud, PJ | 1 |
| Shah, S | 1 |
| Humphries, SE | 1 |
| Ruwald, AC | 1 |
| Westergaard, B | 1 |
| Sehestedt, T | 1 |
| Carey, KM | 1 |
| Comee, MR | 1 |
| Donovan, JL | 1 |
| Kanaan, AO | 1 |
| Poirier, L | 1 |
| Lacourcière, Y | 1 |
| Facchetti, R | 1 |
| Parati, G | 1 |
| Zanchetti, A | 3 |
| Teo, KK | 1 |
| Nerla, R | 1 |
| Di Franco, A | 1 |
| Milo, M | 1 |
| Pitocco, D | 1 |
| Zaccardi, F | 1 |
| Tarzia, P | 1 |
| Sarullo, FM | 1 |
| Villano, A | 1 |
| Russo, G | 1 |
| Stazi, A | 1 |
| Ghirlanda, G | 1 |
| Lanza, GA | 1 |
| Crea, F | 1 |
| Bautista, LE | 1 |
| Vera-Cala, LM | 1 |
| Ferrante, D | 1 |
| Herrera, VM | 1 |
| Miranda, JJ | 1 |
| Pichardo, R | 1 |
| Sánchez Abanto, JR | 1 |
| Ferreccio, C | 1 |
| Silva, E | 1 |
| Oróstegui Arenas, M | 1 |
| Chirinos, JA | 1 |
| Medina-Lezama, J | 1 |
| Pérez, CM | 1 |
| Schapochnik, N | 1 |
| Casas, JP | 1 |
| Aurup, P | 6 |
| Edelman, J | 2 |
| Kristianson, K | 6 |
| Lederballe-Pedersen, O | 9 |
| Omvik, P | 10 |
| Oparil, S | 10 |
| Snapinn, S | 5 |
| Karpov, IuA | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 1 |
| Werkö, L | 1 |
| Vandenbroucke, JP | 1 |
| Grossman, E | 1 |
| Fournier, A | 2 |
| Oprisiu, R | 1 |
| Andrejak, M | 1 |
| Fernandez, L | 1 |
| Achard, JM | 1 |
| Pedersen, OL | 2 |
| Kjeldsen, S | 1 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Lyle, PA | 7 |
| Snapinn, SM | 3 |
| Felmeden, DC | 1 |
| Blann, AD | 1 |
| Spencer, CG | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Helle Berg, S | 1 |
| Høieggen, A | 2 |
| Alderman, MH | 1 |
| Chen, C | 1 |
| Jern, S | 2 |
| Harris, KE | 1 |
| Rokkedal, J | 2 |
| Harris, K | 1 |
| Borch-Johnsen, K | 2 |
| Mogensen, CE | 2 |
| Wan, Y | 2 |
| Hornestam, B | 1 |
| Lehto, M | 1 |
| Slotwiner, DJ | 1 |
| Reims, HM | 1 |
| Brady, WE | 2 |
| de Simone, G | 1 |
| Franklin, SS | 1 |
| Bella, JN | 1 |
| Smith, G | 1 |
| Weber, MA | 2 |
| Bilous, R | 1 |
| Williams, B | 1 |
| Lacy, PS | 1 |
| Thom, SM | 1 |
| Cruickshank, K | 1 |
| Collier, D | 1 |
| Hughes, AD | 1 |
| Thurston, H | 1 |
| O'Rourke, M | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Nielsen, OW | 1 |
| Hall, C | 1 |
| Wergeland, R | 1 |
| Hildebrandt, PR | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 1 |
| Otterstad, JE | 1 |
| Narkiewicz, K | 1 |
| Hedner, T | 1 |
| Blackburn, DF | 1 |
| Lamb, DA | 1 |
| Eurich, DT | 1 |
| Wilson, TW | 1 |
| Dobson, RT | 1 |
| Blackburn, JL | 1 |
| Sica, DA | 1 |
| Pedersen, ME | 1 |
| Boersma, C | 1 |
| Carides, GW | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Postma, MJ | 1 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Flaa, A | 1 |
| Chattopadhyay, A | 1 |
| Fossum, E | 1 |
| Gleim, GW | 1 |
| Kizer, JR | 1 |
| Goyal, RK | 1 |
| Vlietstra, RE | 1 |
| McGoon, MD | 1 |
| Dotzer, F | 1 |
| Gromer, H | 1 |
| Garg, KC | 1 |
| Singhal, KC | 1 |
| Kumar, S | 1 |
| Curb, JD | 1 |
| Cutler, JA | 1 |
| Savage, PJ | 1 |
| Applegate, WB | 2 |
| Black, H | 1 |
| Camel, G | 1 |
| Frost, PH | 1 |
| Gonzalez, N | 1 |
| Guthrie, G | 1 |
| Oberman, A | 2 |
| Rutan, GH | 1 |
| Stamler, J | 1 |
| Berge, KG | 1 |
| Hawkins, CM | 1 |
| Probstfield, J | 1 |
| Davies, RF | 1 |
| Goldberg, AD | 1 |
| Forman, S | 1 |
| Knatterud, GL | 1 |
| Geller, N | 1 |
| Sopko, G | 1 |
| Pratt, C | 1 |
| Deanfield, J | 1 |
| Conti, CR | 1 |
| Eston, RG | 1 |
| Thompson, M | 1 |
| Chazan, R | 1 |
| Black, HR | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Grimm, RH | 1 |
| Hansson, L | 2 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Sleight, P | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Wittes, J | 1 |
| Fakouhi, TD | 1 |
| Bond, MG | 1 |
| Hennig, M | 1 |
| Neiss, A | 1 |
| Dal Palù, C | 1 |
| Magnani, B | 1 |
| Rahn, KH | 1 |
| Reid, J | 1 |
| Rodicio, J | 1 |
| Safar, M | 1 |
| Eckes, L | 1 |
| Ravinetto, R | 1 |
| Vander Hoorn, S | 1 |
| Jackson, RT | 1 |
| Leung, JM | 1 |
| Zaugg, M | 1 |
| Tagliente, T | 1 |
| Lucchinetti, E | 1 |
| Jacobs, E | 1 |
| Krol, M | 1 |
| Bodian, C | 1 |
| Reich, DL | 1 |
| Silverstein, JH | 1 |
| Franse, LV | 1 |
| Pahor, M | 1 |
| Di Bari, M | 1 |
| Shorr, RI | 1 |
| Wan, JY | 1 |
| Somes, GW | 1 |
| Kristiansson, K | 2 |
| Wiedermann, CJ | 1 |
| Hamon, M | 1 |
| Cruickshank, JM | 1 |
| Brown, MJ | 1 |
| Bloom, JM | 1 |
| Fuchs, FD | 1 |
| Wassertheil-Smoller, S | 1 |
| Blaufox, MD | 1 |
| Davis, B | 1 |
| Langford, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Adherence to Antihypertensive Drugs and Statins in the Population of Subjects With Hypertension Followed at SIIA Centers, Using an Innovative Monitoring Based on Hair Analysis[NCT05347823] | 200 participants (Anticipated) | Observational | 2022-05-15 | Not yet recruiting | |||
| The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention[NCT01646437] | Phase 3 | 7,793 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease[NCT01522950] | Phase 2 | 76 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.[NCT01057537] | Phase 3 | 2,004 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Randomized Double Blind Controlled Trial of the Efficacy and Safety of POLYCAP (Quintapill)Versus Its Components in Subjects With at Least One Additional Cardiovascular Risk Factor[NCT00443794] | 2,050 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease[NCT01932450] | Phase 2 | 100 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events[NCT03223441] | 543 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Longitudinal Change of Arterial Stiffness Indices in Relation to Ambulatory Aortic and Branchial Pressure in Long Term Peritoneal Dialysis Patients[NCT03607747] | 40 participants (Anticipated) | Observational | 2018-07-18 | Recruiting | |||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| [NCT00000478] | Phase 3 | 0 participants | Interventional | 1990-11-30 | Completed | ||
| Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy[NCT02511483] | Phase 2 | 10 participants (Actual) | Interventional | 2015-05-18 | Terminated (stopped due to Difficulty with recruitment) | ||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months
| Intervention | mmHg (Mean) |
|---|---|
| Nebivolol | -8.5 |
| Atenolol | -8.5 |
| Placebo | -2.9 |
Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months
| Intervention | (ml/mmHg × 10) (Mean) |
|---|---|
| Nebivolol | 3.2 |
| Atenolol | 2.9 |
| Placebo | 0.2 |
Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months
| Intervention | (ml/mmHg × 100) (Mean) |
|---|---|
| Nebivolol | 2.4 |
| Atenolol | 1.0 |
| Placebo | 0.4 |
Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation. (NCT01522950)
Timeframe: baseline, 9 months
| Intervention | mmHg (Mean) |
|---|---|
| Nebivolol | -9 |
| Atenolol | -13 |
| Placebo | -3.2 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
16 reviews available for atenolol and Cardiovascular Diseases
| Article | Year |
|---|---|
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Comorbidity | 2022 |
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Cardiovascular Diseases; Ce | 2021 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Beta-adrenergic antagonists in hypertension: a review of the evidence.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovasc | 2009 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydr | 2012 |
The evolving role of β-adrenergic receptor blockers in managing hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Cardiac Output; Cardiovascular Dise | 2012 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2004 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Will ASCOT change the form of anti-hypertensive therapy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2006 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
The vasodilatory beta-blockers.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Antioxidants; Atenolol; Benzopyrans; Blood Pre | 2007 |
[Indications spectrum for beta-1-selective adrenergic receptor blockers].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseas | 1993 |
[Atenolol in treatment of patients with airway obstruction].
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Atenolol; Cardiovascular Diseases; Coronary Disease | 1996 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
64 trials available for atenolol and Cardiovascular Diseases
| Article | Year |
|---|---|
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2021 |
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; | 2017 |
Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female | 2017 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; | 2018 |
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2018 |
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiova | 2013 |
Evaluation of a technique to measure heart rate variability in anaesthetised cats.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Anesthesia; Animals; An | 2014 |
Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlor | 2014 |
Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; | 2014 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme In | 2015 |
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2014 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
[No antihypertensive drugs for frail elderly?].
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cause of Death; Ch | 2016 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2009 |
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diastole; Electrocardiography; Fem | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting E | 2009 |
Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Dose-Response Relation | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolo | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Cardiovascular Diseases; Cross-Sectional Studi | 2010 |
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2011 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2012 |
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Bloc | 2012 |
Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blo | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
Topics: Atenolol; Benzazepines; Brachial Artery; Cardiovascular Diseases; Cyclic Nucleotide-Gated Cation Cha | 2012 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2003 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cholesterol; Do | 2003 |
A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes T
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Brachial Artery; Card | 2003 |
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; End | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Prognostic significance of left ventricular mass change during treatment of hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Electrocardiograph | 2004 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Doubl | 2006 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabetes Compli | 2007 |
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlor | 1996 |
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; Double-Blind Metho | 1995 |
Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Atenolol; Calcium Channel Blocker | 1997 |
Use of ratings of perceived exertion for predicting maximal work rate and prescribing exercise intensity in patients taking atenolol.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Atenolol; Cardiovascular Diseases; Exercise Test; | 1997 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis.
Topics: Adrenergic beta-Antagonists; Aged; Arteriosclerosis; Atenolol; Blood Pressure; Calcium Channel Block | 1998 |
Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Algorithms; Atenolol; Blood Pressure; Cardiova | 1999 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Cardio | 2002 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Cardiovascular Diseases | 1992 |
51 other studies available for atenolol and Cardiovascular Diseases
| Article | Year |
|---|---|
Utilizing quantitative dried blood spot analysis to objectively assess adherence to cardiovascular pharmacotherapy among patients at Kenyatta National Hospital, Nairobi, Kenya.
Topics: Atenolol; Cardiovascular Agents; Cardiovascular Diseases; Dried Blood Spot Testing; Female; Hospital | 2023 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liqu | 2020 |
Effect of atenolol pre-treatment in heart damage in a model of intestinal ischemia-reperfusion.
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Heart; Intestines; Male; Mesent | 2017 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost | 2019 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
The effectiveness of metoprolol versus atenolol on prevention of all-cause and cardiovascular mortality in a large Chinese population: a cohort study.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Asian People; Atenolol; Cardiovascular Diseases; Cohor | 2014 |
Study of the Biotransformation of Tongmai Formula by Human Intestinal Flora and Its Intestinal Permeability across the Caco-2 Cell Monolayer.
Topics: Atenolol; Bacteria; Biological Transport; Biotransformation; Caco-2 Cells; Cardiovascular Diseases; | 2015 |
Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte.
Topics: Actin Cytoskeleton; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animal | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumeth | 2008 |
Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseases; Contraindi | 2008 |
Diabetes and hypertension: which is the best approach?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Ch | 2009 |
Atenolol is dead: long live beta-blockade.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp | 2009 |
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atenolol; Calcium Channel Blockers; Calcium Channel | 2009 |
[Beta-blocking agents in the perioperative period of the non-cardiac surgery].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiovascular Disea | 2010 |
Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Atenolol; Benzopyrans; Blood Pressure; Cardiovascular D | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data.
Topics: Antihypertensive Agents; Atenolol; Captopril; Cardiovascular Diseases; Cost of Illness; Developing C | 2010 |
More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension.
Topics: Antihypertensive Agents; Aorta; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery; Card | 2011 |
Does atenolol reduce adverse cardiovascular outcomes in adult patients with hypertension?
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension | 2011 |
Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disea | 2011 |
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
Topics: Adult; Alleles; Atenolol; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, | 2012 |
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Bene | 2013 |
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Drug Industry; Humans; Hype | 2003 |
More on the LIFE study.
Topics: Atenolol; Cardiovascular Diseases; Cause of Death; Conflict of Interest; Data Collection; Drug Indus | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihyperten | 2003 |
Effects of losartan in hypertension without vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hyp | 2004 |
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Electrocardiography; Female; Human | 2004 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.
Topics: Amlodipine; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
[Kidney protection leads to heart protection, too].
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2006 |
Beta-blockers as sub-optimal treatment for hypertension: time for first-line therapy revision?
Topics: Adrenergic beta-Antagonists; Aging; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diab | 2006 |
Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2007 |
Hypertension treatment: how important is consistency of effect?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure Determination; Cardiovascular Diseases; Cohort Stu | 2007 |
Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiov | 2007 |
Beta-adrenergic blockers. Choosing among them.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseases; Humans; Kinetics; Metoprolol; Nadolo | 1984 |
Monitoring the adverse profile of atenolol--a collaborative study.
Topics: Atenolol; Cardiovascular Diseases; Humans; Middle Aged | 1993 |
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiovascular Diseases; Celiprolol; Female; Hum | 1997 |
Diabetes and not lack of treatment with atenolol predicts decreased survival after noncardiac surgery.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Diseases; Diabetes Complications; Humans | 1999 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Melli | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Heart Rate; | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Human | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disea | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diure | 2002 |